테폭살린

비스테로이드성 항염증제 (NSAID)

테폭살린은 시클로옥시게나제(COX)와 리폭시게나제(LOX) 경로를 모두 억제하는 독특한 **이중 억제제**입니다. 주로 **반려견의 골관절염**과 관련된 통증 및 염증 치료에 사용됩니다. * 구강 붕해정(입에서 녹는 알약) 형태로 제공되어 알약을 먹이기 힘든 개에게 매우 유용합니다. * 류코트리엔 억제 효과가 있어 반려견의 알레르기 질환에 대한 보조 치료제로서의 가능성도 관심을 받고 있습니다. * **임상 팁**: LOX 억제로 인한 이론적인 위장관 보호 효과에도 불구하고, 임상 데이터에 따르면 다른 최신 FDA 승인 COX-2 선택적 NSAID에 비해 구토와 설사를 더 많이 유발할 수 있습니다.

작용 기전: Tepoxalin blocks the arachidonic acid cascade at two key points: * **Cyclooxygenase (COX-1 and COX-2)** → Decreases production of pro-inflammatory **prostaglandins** (mediators of pain, hyperpyrexia, and inflammation). * **5-Lipoxygenase (5-LOX)** → Decreases production of **leukotrienes** (e.g., LTB4). *Pharmacological Note*: LTB4 is a potent chemoattractant for neutrophils and contributes to GI mucosal damage by increasing cytokine production and release of proteinases. By inhibiting LOX, tepoxalin theoretically mitigates the GI ulcerogenic effects typically seen with COX-1 inhibition, though clinical GI side effects still occur. LOX inhibition in dogs persists for only about 6 hours after dosing.

동물 종별 용량

Dogs

Pain and inflammation associated with osteoarthritis · 20 mg/kg PO (or 10 mg/kg PO) on first day; subsequently give 10 mg/kg PO once daily · PO · q24h · Based on clinical response and patient tolerance · On first day of treatment give 20 mg/kg PO (or 10 mg/kg PO); subsequently give 10 mg/kg PO once daily.

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

Prior hypersensitivity reactions to tepoxalin
Active gastrointestinal ulcers
Dogs weighing less than 3 kg (cannot be accurately dosed)
Dogs less than 6 months old (safety not established)

이상반응

Diarrhea
Vomiting
Anorexia/inappetence
Enteritis
Lethargy
Incoordination (<1%)
Incontinence (<1%)
Increased appetite (<1%)
Eating grass (<1%)
Flatulence (<1%)
Hair loss (<1%)
Trembling (<1%)

약물 상호작용

Aspirin · May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
Corticosteroids · May increase the occurrence of gastric ulceration; avoid concomitant use
Digoxin · NSAIDs may increase serum levels of digoxin
Fluconazole · May increase plasma levels of tepoxalin (extrapolated from human celecoxib data)
Furosemide · NSAIDs may reduce saluretic and diuretic effects
Methotrexate · Serious toxicity has occurred with concomitant NSAID use; use with extreme caution
Nephrotoxic Drugs (e.g., aminoglycosides, amphotericin B) · May enhance the risk of nephrotoxicity
Other NSAIDs · May increase the risk of gastrointestinal toxicity (e.g., ulceration, bleeding, vomiting, diarrhea)
Warfarin · Tepoxalin is highly protein bound (98-99%); may displace warfarin and increase bleeding risk. Monitor closely.

모니터링

Clinical efficacy (improvement in mobility/pain)
Baseline and periodic CBC
Chemistry panel (including bilirubin and serum creatinine)
Signs associated with adverse effects (GI effects, appetite, vomiting, diarrhea, etc.)

과용량

Information on acute overdosage is limited. Chronic overdosage (300 mg/kg/day for 6 months) in dogs caused decreases in total protein, albumin, and calcium concentrations, with gastric lesions noted at necropsy. An acute overdose may cause significant GI distress, ulceration, and GI bleeding. * **Treatment**: Treat supportively. Monitor CBC, hydration status, renal function, and for evidence of GI bleeding. Contact an animal poison control center for further guidance.

VetSheet 약물 레퍼런스는 면허 수의 전문가를 위한 임상 의사결정 보조 도구이며, 전문적 판단이나 제조사의 최신 라벨을 대신하지 않습니다.